About CereGate

CereGate is developing a Computer-Brain-Interface (“BCI”) platform that is already capable to successfully submit information into the human brain. The revolutionary software platform is clinically validated and allows for enhanced treatment of various neurological and psychiatric disorders. The CereGate platform is able to transmit information into the brain („Mind-Writing“), by utilizing state of the art neuromodulation technology. While focusing first on improving gait symptoms for Parkinson patients, CereGate aims to become a key enabling tech¬nology in the field of rehabilitation and (neuro)prosthetics.

Press releases

12. January 2022

CereGate, the preeminent Computer-Brain-Interface Software Platform, advances in clinical development and secures financing from leading deep tech and mental health investors 468 Capital and re.Mind Capital

In the thriving field of neuroscience, CereGate is poised to revolutionize the treatment of neurological disorders by interacting with the human brain through a unique software-first approach. After making strides in the clinical development, including FDA Breakthrough designation for its first application in Deep Brain Stimulation Freezing of Gait Therapy (FOG-LIGHTS) and launching a clinical trial in the US, CereGate achieves additional funding to further accelerate the development of n
3. September 2020

Computer-Brain-Interface Company CereGate Closed Series A Financing Round

The Healthtech VC Heal Capital led the round with participation of HTGF and TruVenturo CereGate, a leading German neurostimulation company developing a software-based Computer-Brain-Interface (CBI), today announced the successful closing of a series A financing round led by the new European healthtech VC Heal Capital with participation from the existing investors High-Tech Gründerfonds (HTGF) and TruVenturo. The parties agreed to not disclose any further details of the financing round.
23. January 2020

CereGate GmbH receives financing from High-Tech Gründerfonds to accelerate development of a new software platform for neuromodulation therapy

CereGate enables “Mind-Writing”, i.e. it directly transmits information to the brain The CereGate system is successfully validated in a clinical study Study results are currently presented during the NANS-Meeting in Las Vegas High-Tech Gründerfonds enters with a capital increase and convertible The financing shall accelerate development of the system for new indications in stroke rehabilitation, neuroprosthetics and computer/brain-interfacing   According to WHO more than 1

Info & Contact

Dr. Bálint Várkuti


CereGate GmbH
Große Reichenstraße 27
20457 Hamburg

In portfolio

06. Dec 2019

Kay G. Balster

Principal / Authorized signatory